Vera Therapeutics announced a major milestone in drug development on January 7, 2026, when the U.S. Food and Drug Administration granted Priority Review to the Biologics License Application (BLA) for…
A comprehensive multi-omics analysis has identified the terminal ileum as a critical source of pathogenic antibody-producing cells in IgA nephropathy (IgAN), one of the most common primary glomerulonephritis worldwide. This…
As reported on PharmaBiz, Renalys Pharma has reported encouraging topline data from its Phase III trial evaluating sparsentan (RE-021), an oral dual endothelin and angiotensin II receptor antagonist, in Japanese…
Vera Therapeutics has taken a major step toward transforming treatment for immunoglobulin A nephropathy (IgAN), submitting a Biologics License Application to the U.S. Food and Drug Administration through the Accelerated…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
